An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of IVACs caused by Enterobacterales in critically ill adult patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of IVACs caused by Enterobacterales in critically ill adult patients
Authors
Keywords
-
Journal
Expert Review of Anti-Infective Therapy
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2021-09-07
DOI
10.1080/14787210.2021.1976145
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors
- (2021) Milo Gatti et al. Expert Review of Clinical Pharmacology
- Correction to: Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature
- (2021) Simone Meini et al. INFECTION
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
- (2020) Sara Alosaimy et al. Open Forum Infectious Diseases
- Population structure of KPC carbapenemase-producing Klebsiella pneumoniae in a long-term acute-care rehabilitation facility: identification of a new lineage of clonal group 101, associated with local hyperendemicity
- (2020) Fabio Arena et al. Microbial Genomics
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017
- (2020) Jean-Louis Vincent et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
- (2020) Mercedes Delgado-Valverde et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
- (2020) Luzelena Caro et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline
- (2020) Sara E Boyd et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
- (2020) Ivan Titov et al. CLINICAL INFECTIOUS DISEASES
- In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria
- (2020) Shazad Mushtaq et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Evaluation of the FilmArray® Pneumonia Plus Panel for Rapid Diagnosis of Hospital-Acquired Pneumonia in Intensive Care Unit Patients
- (2020) Lise Crémet et al. Frontiers in Microbiology
- Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
- (2020) Naoki Kohira et al. Journal of Global Antimicrobial Resistance
- Rationalizing antimicrobial therapy in the ICU: a narrative review
- (2019) Jean-François Timsit et al. INTENSIVE CARE MEDICINE
- AmpC β-lactamase-producing Enterobacterales: what a clinician should know
- (2019) Simone Meini et al. INFECTION
- Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
- (2019) Takayuki Katsube et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam
- (2019) Matthaios Papadimitriou-Olivgeris et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia
- (2019) Wang-Da Liu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
- (2019) Sandra Mikhail et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis
- (2019) João Paulo Telles et al. Expert Review of Anti-Infective Therapy
- Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae
- (2019) Dominika Ojdana et al. Microbial Drug Resistance
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
- (2019) Joshua P. Metlay et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
- (2019) Basem M. Alraddadi et al. BMC INFECTIOUS DISEASES
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections
- (2019) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases
- (2019) Laura Benchetrit et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia
- (2019) David L. Paterson et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems
- (2019) Sock Hoon Tan et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
- (2019) Stephen Poole et al. JOURNAL OF INFECTION
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- (2018) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Extensively Drug-Resistant or Pandrug-Resistant Sequence Type 147 and 101 OXA-48-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Patients in an Intensive Care Unit
- (2018) Kalliope Avgoulea et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
- (2018) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae
- (2018) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- New antibiotics for ventilator-associated pneumonia
- (2018) Matteo Bassetti et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infection
- (2018) Fusun Can et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Treatment of Infections with OXA-48 producing Enterobacteriaceae
- (2018) Adam Stewart et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria
- (2018) Matteo Bassetti et al. Current Opinion in Critical Care
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM
- (2018) C. De la Calle et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
- (2017) J. Dobias et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
- (2017) Andrew Rhodes et al. INTENSIVE CARE MEDICINE
- Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
- (2017) Juan J. Castón et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection
- (2017) Evelyn Shaw et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- How Should We Treat Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae?
- (2017) Jean-François Timsit et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae
- (2017) Yun Liao et al. Experimental and Therapeutic Medicine
- Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program
- (2016) Elizabeth Temkin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study
- (2016) D. Koulenti et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
- (2015) Eric Wenzler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates
- (2015) Nan-Yao Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d’Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789)
- (2015) Mariateresa Del Franco et al. BMC MICROBIOLOGY
- Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia
- (2015) P. D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae
- (2015) Hadas Ofer-Friedman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens
- (2015) David P. Nicolau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia
- (2014) M. J. Siedner et al. CLINICAL INFECTIOUS DISEASES
- Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae
- (2014) Lisa M. Blanchette et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae
- (2013) Pranita D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies
- (2013) Wilhelmina G Melsen et al. LANCET INFECTIOUS DISEASES
- Attributable Mortality of Ventilator-Associated Pneumonia
- (2011) Maarten Bekaert et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Moxifloxacin vs Ampicillin/Sulbactam in Aspiration Pneumonia and Primary Lung Abscess
- (2008) S. R. Ott et al. INFECTION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search